FIN.DE TUBIZE ACT.NOUV.

F:FTD Germany Biotechnology
Market Cap
$9.66 Billion
€9.41 Billion EUR
Market Cap Rank
#3173 Global
#288 in Germany
Share Price
€211.50
Change (1 day)
-1.63%
52-Week Range
€106.60 - €246.50
All Time High
€246.50
About

Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. It engages in discovering and developing treatments for patients suffering from serious illnesses that affects immune system or central nervous system. The company was incorporated in 1928 and is based in Brussels, Belgium.

FIN.DE TUBIZE ACT.NOUV. (FTD) - Net Assets

Latest net assets as of : €- EUR

Based on the latest financial reports, FIN.DE TUBIZE ACT.NOUV. (FTD) has net assets worth €- EUR as of .

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets €-
% of Total Assets 0%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility N/A

FIN.DE TUBIZE ACT.NOUV. - Net Assets Trend (None–None)

This chart illustrates how FIN.DE TUBIZE ACT.NOUV.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for FIN.DE TUBIZE ACT.NOUV. (None–None)

The table below shows the annual net assets of FIN.DE TUBIZE ACT.NOUV. from None to None.

Year Net Assets Change
No yearly data available.

Equity Component Analysis

This analysis shows how different components contribute to FIN.DE TUBIZE ACT.NOUV.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • No equity composition insights available.

FIN.DE TUBIZE ACT.NOUV. Competitors by Market Cap

The table below lists competitors of FIN.DE TUBIZE ACT.NOUV. ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in FIN.DE TUBIZE ACT.NOUV.'s equity between the two most recent reporting periods.

Insufficient data available to analyze equity growth attribution.

Book Value vs Market Value Analysis

This analysis compares FIN.DE TUBIZE ACT.NOUV.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Insufficient data available to analyze book value vs market value.

Capital Efficiency Dashboard

This dashboard shows how efficiently FIN.DE TUBIZE ACT.NOUV. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Insufficient data available to analyze capital efficiency metrics.

Industry Comparison

This section compares FIN.DE TUBIZE ACT.NOUV.'s net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $1,291,084,078
  • Average return on equity (ROE) among peers: -24.49%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
FIN.DE TUBIZE ACT.NOUV. (FTD) €- N/A N/A $4.17 Billion
09R (09R) $-3.01 Million 0.00% 0.00x $11.12 Million
IDORSIA AG (19T) $-968.72 Million 0.00% 0.00x $532.51 Million
1S90 (1S90) $-44.86 Million 0.00% 0.00x $51.72 Million
Strategic Partners A/S (1TB0) $14.24 Million -182.90% 0.36x $1.31 Million
25K0 (25K0) $-16.66 Million 0.00% 0.00x $102.39 Million
2BO (2BO) $-37.78 Million 0.00% 0.00x $6.23 Million
Intervacc AB (publ) (2E9) $237.93 Million -43.23% 0.09x $3.46 Million
2F5 (2F5) $-4.57 Million 0.00% 0.00x $2.14 Million
2H0 (2H0) $14.92 Million -17.30% 0.56x $9.25 Million
GNI Group Ltd (3G6) $13.72 Billion -1.46% 0.26x $772.60 Million